Spero Therapeutics (SPRO) Assets Average (2017 - 2025)
Spero Therapeutics (SPRO) has disclosed Assets Average for 9 consecutive years, with $58.1 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Assets Average fell 59.2% year-over-year to $58.1 million, compared with a TTM value of $58.1 million through Sep 2025, down 59.2%, and an annual FY2024 reading of $146.5 million, down 4.64% over the prior year.
- Assets Average was $58.1 million for Q3 2025 at Spero Therapeutics, down from $69.9 million in the prior quarter.
- Across five years, Assets Average topped out at $175.0 million in Q1 2024 and bottomed at $58.1 million in Q3 2025.
- Average Assets Average over 5 years is $120.3 million, with a median of $122.9 million recorded in 2024.
- The sharpest move saw Assets Average soared 60.8% in 2023, then plummeted 59.2% in 2025.
- Year by year, Assets Average stood at $157.9 million in 2021, then crashed by 40.06% to $94.6 million in 2022, then soared by 52.94% to $144.7 million in 2023, then fell by 15.13% to $122.9 million in 2024, then plummeted by 52.67% to $58.1 million in 2025.
- Business Quant data shows Assets Average for SPRO at $58.1 million in Q3 2025, $69.9 million in Q2 2025, and $94.1 million in Q1 2025.